Isopeptidase-Fluorogenic Assays

Transglutaminases are able to also cleave the isopeptide bond. This principle is used to provide easy to handle, robust and precise fluorogenic assays suitable for screening of compound libraries and drug development. Further, it reliably detects levels as low as 5% of the physiological amount of FXIIIa (0.05 IU/ml) in plasma (Oertel et al., Anal. Biochem. 2007, 367:152-8).

Mechanism: transglutaminase cleaves the isopeptide bond releasing the dark quencher (2,4-dinitrophenyl) linked to the cadaverine spacer. Subsequently, the increase of fluorescence results from the N-terminally attached fluorophore 2-aminobenzoyl (2-Abz).

Zedira offers two different modified peptides A101 and A102 and the related assay kits F001 and F002. The transglutaminase family members discriminate between the peptides as shown in the table.

   Isopeptidase acitivity assay A101 and A102 principle
Isopeptidase activity Assay A101 and A102  

Art. No.
A101 FXIII-Assay Substance,
10 mg
520 €
A102 TG2-Assay Substance,
10 mg
415 €
F001 FXIII-Assay Kit
Based on substrate A101
1 Kit
575 €
F002 Tissue Transglutaminase Assay Kit
Based on substrate A102
1 Kit
520 €

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland